Online Program

335127
Community impact of a primary-care clinic-based Medically Assisted Treatment program for pregnant, opioid dependent women


Monday, November 2, 2015 : 2:50 p.m. - 3:10 p.m.

Wendy Johnson, MD, MPH, La Familia Medical Center, Santa Fe, NM
Suzanne Burlone, MD, La Familia Medical Center, Santa Fe, NM
Myriam Salazar, La Familia Medical Center
Between 2001 and 2010, the New Mexico drug overdose death rate jumped 60%. Since then, our state has consistently led the nation for overdose deaths and narcotic use. The epidemic centers on young adults, including women of child bearing age. In Santa Fe, up to 20 women per year were giving birth to drug-dependent infants. There is effective and safe addiction treatment available during pregnancy, but until recently, women could access these services in only one program in the state, at the University of New Mexico in Albuquerque.

Faced with this huge public health the problem and knowing the difficulty drug-using pregnant women had accessing care, La Familia Medical Center launched one of the first community-clinic-based comprehensive pregnancy care and opioid treatment programs in the country. Starting in late 2013, we began offering drug dependent women comprehensive care of their pregnancy, including delivery, and family centered care for their children and partners as well. To date we have treated over 70 women and partners and delivered 25 babies with no significant effects of narcotic dependence. Santa Fe County has one referral hospital, giving us an opportunity to analyze the impact of the program on the entire community via Christus St. Vincent's Hospital data.  

We will present program statistics from the first full year of the program to the year before program implementation.  Data include the number of Neonatal Abstinence Syndrome (NAS) diagnoses, average length of stay for all infants diagnosed with NAS in both years and for all infants delivered to buprenorphine patients in 2014.  We will also present data on the characteristics of women and infants in the treatment program compared to those in 2013 diagnosed with NAS including timing and frequency of prenatal care, birthweight, and birth outcomes.  Preliminary data analysis shows that average length of stay and NAS diagnoses have dropped dramatically from 2013 to 2014 in our community.   

Several states have passed laws criminalizing drug use in pregnancy and discouraging women from seeking the prenatal care and treatment they so desperately want and need. We will also discuss the costs and publc health effects of both approaches. 

We conclude that comprehensive primary care including buprenorphine treatment, substance abuse counseling, pregnancy care and family centered care for opioid using women and their children and partners is effective, has significant public health benefits, and can be feasibly implemented by community clinics.

Learning Areas:

Advocacy for health and health education
Clinical medicine applied in public health
Other professions or practice related to public health
Provision of health care to the public
Public health or related public policy

Learning Objectives:
Explain the public health impact of providing medically assisted drug treatment and comprehensive early prenatal care for opioid using pregnant women in Santa Fe. Compare the public health impact and cost of medically assisted drug treatment for pregnant women with other approaches that criminalize drug use in pregnancy.

Keyword(s): Drug Abuse Treatment, Maternal and Child Health

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: 20 years experience as a primary care provider, 3 years experience as a Medical Director of an FQHC. Clinical Professor of Public Health at the University of Washington with 10 years of teaching experience in Global Health and Health Services. Architect of the program described and oversaw the implementation and evaluation. Provider of prenatal care and buprenorphine treatment for the last 2 years.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.